Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT04582318
Ignite Creation Date: 2024-05-06 @ 3:18 PM
Last Modification Date: 2024-10-26 @ 1:46 PM
Study NCT ID: NCT04582318
Protocol Section: NCT04582318
Start Identification Module Data
Expand Identification Module Data
Brief Title: A Phase 12 Study to Assess the Safety Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects and to Assess the Safety PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19
Official Title: A Randomized Double Blind Placebo Controlled Combined Phase 12 Single Dose and Multiple Dose Study to Assess the Safety Tolerability and Pharmacokinetics of NGM621 in Healthy Volunteers and the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy in Subjects With Confirmed SARS-CoV-2 Infection
Acronym: None
Organization: NGM Biopharmaceuticals Inc
Organization Class: INDUSTRY
Organization Study ID: 621-CP-102
Start Status Module Data
Status Verified Date: 2022-02
Overall Status: TERMINATED
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: NGM Biopharmaceuticals Inc
Lead Sponsor Class: INDUSTRY
Lead Sponsor: NGM Biopharmaceuticals Inc
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload